Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Average Target Price of $8.20

Key Points

• Analysts are broadly cautious on Fulcrum Therapeutics, with a consensus “Reduce” rating from 12 firms: four sells, seven holds and one buy. The average 12-month price target is $8.20 versus the stock’s $3.72 opening price.
• Institutional ownership stands at 89.83%, with BlackRock, Nantahala Capital Management and other funds recently establishing or increasing positions.
• Fulcrum reported a quarterly loss of $0.34 per share, missing the $0.24 consensus estimate, while analysts expect a full-year loss of approximately $0.60 per share. Its lead program, losmapimod, is being developed for the rare muscle disease FSHD.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been assigned an average recommendation of "Reduce" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $8.20.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Fulcrum Therapeutics in the 2nd quarter worth $32,297,000. Bank of New York Mellon Corp bought a new stake in Fulcrum Therapeutics in the second quarter worth $566,000. Siren L.L.C. boosted its position in Fulcrum Therapeutics by 20.5% during the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company's stock valued at $18,024,000 after buying an additional 400,000 shares during the period. Nantahala Capital Management LLC purchased a new stake in Fulcrum Therapeutics during the second quarter valued at about $20,038,646. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Fulcrum Therapeutics during the second quarter valued at about $2,728,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Trading Up 0.5%

FULC opened at $3.72 on Wednesday. The stock has a market capitalization of $283.84 million, a P/E ratio of -3.07 and a beta of 2.63. The stock has a 50-day moving average price of $3.78 and a 200-day moving average price of $4.74. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). On average, equities research analysts predict that Fulcrum Therapeutics will post -0.60 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically defined diseases. The company uses its biology and drug-discovery platform to identify molecular targets that can alter gene expression and address the underlying causes of serious disorders.

Fulcrum's lead investigational program has been losmapimod, a small-molecule p38 alpha and beta mitogen-activated protein kinase inhibitor studied as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive muscle disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.